New drug cocktail aims to tackle tough lymphoma in vulnerable patients
NCT ID NCT06357676
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of three drugs—glofitamab, ibrutinib, and obinutuzumab—in people with mantle cell lymphoma who are either 65 or older, or between 18 and 64 with high-risk features. The goal is to see if the combo is safe and can shrink or eliminate tumors. Participants will receive the drugs intravenously and by mouth, along with regular scans and blood tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glofitamab, ibrutinib, and obinutuzumab
What this could lead to
If successful, this combination could offer a new, more effective treatment option for mantle cell lymphoma, especially for older or high-risk patients.
What could go wrong
This is an early-phase trial with only 27 participants, so results may not apply broadly. Side effects like cytokine release syndrome or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact